Impact of biologic and immunomodulatory therapy on SARS-CoV-2 infection and immunity in patients with inflammatory bowel disease
Latest Information Update: 03 Aug 2022
At a glance
- Drugs Azathioprine (Primary) ; Infliximab (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary) ; Vedolizumab (Primary) ; AZD 1222; Tozinameran
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Pharmacodynamics
- Acronyms CLARITY IBD
- 28 Jul 2022 Results published in the Gut
- 13 Aug 2021 Status changed from active, no longer recruiting to completed.
- 06 May 2021 New trial record